Table 1.

Top hits of U87MG and U87MG-R50 drug screens. Drugs that have significant effect on GBM cells as single agents are indicated in bold.

		U87MG Screen		U87MG-R50 Screen
Therapeutic class	Drug Name	Drug alone % cell viability ± SEM (% of control )	In combination with TRAIL % cell viability ± SEM (% of control)	Drug alone % cell viability ± SEM (% of control )	In combination with TRAIL % cell viability ± SEM (% of control)
Antibacterial	Doxorubicin hydrochloride	39 ± 8.1	13 ± 0.76	64 ± 4.1	12 ± 0.77
	Alexidine dihydrochloride	62 ± 5.1	6.4 ± 1.2
	Monensin sodium salt	62 ± 8.8	24 ± 0.44	69 ± 2.3	37 ± 5.1
	Daunorubicin hydrochloride	65 ± 5.5	8.0 ± 0.76	58 ± 6.2	11 ± 1.3
	Methyl benzethonium chloride	72 ± 1.4	8.3 ± 2.7	76 ± 3.7	38 ± 22
	Cycloheximide	73 ± 5.9	3.2 ± 4.7	73 ± 10	12 ± 2.8
	Benzethonium chloride	77 ± 7.8	12 ± 4.4	89 ± 18	30 ± 12
	Amphotericin B	84 ± 5.5	21 ± 3.7
	Thiostrepton			84 ± 1.2	35 ± 4.4
Antineoplastic	Camptothecine (S,+)	61 ± 6.1	5.1 ± 0.40	66 ± 4.9	8.1 ± 0.37
	Azacytidine-5	74 ± 5.5	17 ± 0.91
	Vorinostat	75 ± 7.3	16 ± 2.7	81 ± 14	26 ± 0.10
	Topotecan	78 ± 4.5	9.3 ± 0.42	66 ± 7.3	14 ± 2.9
	Mitoxantrone dihydrochloride	91 ± 1.8	1.7 ± 0.16	76 ± 1.8	3.1 ± 0.68
Cardiac glycosides	Lanatoside C	31 ± 7.3	10 ± 2.1	37 ± 2.1	15 ± 0.37
	Digitoxigenin	44 ± 6.3	10 ± 3.2	41 ± 2.5	12 ± 2.3
	Proscillaridin A	42 ± 4.8	14 ± 2.2	38 ± 1.9	19 ± 1.4
	Digoxigenin	52 ± 2.6	6.9 ± 0.70	52 ± 4.7	11 ± 1.1
	Digoxin	74 ± 7.9	13 ± 3.5	35 ± 1.7	13 ± 2.6
Immuno-suppressant	Cyclosporin A	84 ± 4.3	21 ± 1.2
Metabolism	Pyrvinium pamoate	52 ± 1.6	2.8 ± 0.28	56 ± 10	7.6 ± 1.7
Antihelmintic	Niclosamide	41 ± 0.74	3.4 ± 0.21	70 ± 2.6	11 ± 3.6
	Quinacrine dihydrochloride	61 ± 2.2	1.5 ± 0.37	60 ± 7.8	3.0 ± 0.77
Antihistaminic	Terfenadine	62 ± 6.7	27 ± 2.8
	Astemizole	64 ± 3.4	26 ± 2.7
Antiseptic	Thonzonium bromide	67 ± 3.1	3.1 ± 0.81	62 ± 7.0	8.1 ± 4.2
Antispastic	Pinaverium bromide	81 ± 0.97	27 ± 7.3
Threshold for % cell viability		64%	29%	67%	40%